Alkermes (ALKS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Alkermes

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$46.07+0.04(<0.01%)Pre-market

Market Cap

$7.80B

P/E

118.0x

P/S

4.7x

P/B

4.3x

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

How this company scores

WeakMetricSide Score: 47/100

Grade capped at D — Interest coverage below 1× (0.7x) — earnings cannot cover interest. Strongest: Cash & Earnings Quality (15/25); weakest: Profitability (9/25).

Profitability9/25

Growth12/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality15/25

Strengths

Cash-backed earningsImproving margins

Grade capped at D

Interest coverage below 1× (0.7x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 118.0x5y range 10.5x – 118.0x

Currently above its 13-quarter median.

P/S · 4.7x5y range 2.7x – 4.7x

Currently above its 20-quarter median.

P/B · 4.3x5y range 2.5x – 4.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 69.0% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Share Dilution

Watch

Shares outstanding rose 2.2% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $7.80B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.67B
Q. Revenue: $496.01M
TTM EBITDA: $194.79M
TTM Op. Income: $117.26M
Q. Op. Income: $18.35M
TTM Net Income: $66.12M
Q. Net Income: $501,000
EPS: $0
Shares Out.: $167.03M

$1.67B in TTM revenue grew 10.8% YoY, reaching $496.01M last quarter. TTM EBITDA of $194.79M and TTM operating income of $117.26M show growth is flowing through to the bottom line. TTM net income of $66.12M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 80.2%
EBITDA Margin: 9.8%
Op. Margin: 3.7%
Net Margin: 0.1%

Op. margin of 3.7% is down 20.1% YoY — costs are rising relative to revenue. Net margin at 0.1% and gross margin of 80.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 84% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 118.0x
P/S Ratio: 4.7x
P/B Ratio: 4.3x

At 118.0x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 4.7x and P/B of 4.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $4.39B
Cash: $511.53M
Long-Term Debt: $1.48B
Book Value: $1.81B
D/E Ratio: 0.8
Debt/EBITDA: 30.4

With $4.39B in assets and $1.48B in long-term debt, D/E is 0.8and book value is $1.81B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 0% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $145.18M
TTM Free Cash Flow: $221.65M
FCF Margin: 13.3%
FCF / Net Income: 3.4

TTM FCF of $221.65M on $145.18M in operating cash flow. The FCF / Net Income ratio of 3.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.